 SALT LAKE CITY, June 28, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries, Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced that it has been added as a member of the U.S. small-cap Russell 2000 Index and the all-cap Russell 3000 Index, effective after the U.S. market opens today, June 28, 2021, as part of the 2021 Russell indexes reconstitution. 